We’re moving! Datasets in the NIAGADS database are being transitioned to the DSS database, click to learn more.

A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.

TitleA potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin.
Publication TypeJournal Article
Year of Publication2016
AuthorsDeming, Y, Xia, J, Cai, Y, Lord, J, Holmans, P, Bertelsen, S, Holtzman, D, Morris, JC, Bales, K, Pickering, EH, Kauwe, J, Goate, A, Cruchaga, C
Corporate AuthorsAlzheimer's Disease Neuroimaging Initiative (ADNI)
JournalNeurobiol Aging
Volume37
Pagination208.e1-208.e9
Date Published2016 Jan
ISSN1558-1497
KeywordsAged, Aged, 80 and over, Alzheimer Disease, Apolipoprotein E4, Apolipoproteins E, Biomarkers, Clusterin, Endophenotypes, Female, Gene Ontology, Genome-Wide Association Study, Humans, Immunity, Male, Nerve Degeneration, Wound Healing
Abstract

Genome-wide association studies have associated clusterin (CLU) variants with Alzheimer's disease (AD). However, the role of CLU on AD pathogenesis is not totally understood. We used cerebrospinal fluid (CSF) and plasma CLU levels as endophenotypes for genetic studies to understand the role of CLU in AD. CSF, but not plasma, CLU levels were significantly associated with AD status and CSF tau/amyloid-beta ratio, and highly correlated with CSF apolipoprotein E (APOE) levels. Several loci showed almost genome-wide significant associations including LINC00917 (p = 3.98 × 10(-7)) and interleukin 6 (IL6, p = 9.94 × 10(-6), in the entire data set and in the APOE ε4- individuals p = 7.40 × 10(-8)). Gene ontology analyses suggest that CSF CLU levels may be associated with wound healing and immune response which supports previous functional studies that demonstrated an association between CLU and IL6. CLU may play a role in AD by influencing immune system changes that have been observed in AD or by disrupting healing after neurodegeneration.

DOI10.1016/j.neurobiolaging.2015.09.009
Alternate JournalNeurobiol. Aging
PubMed ID26545630
PubMed Central IDPMC5118651
Grant ListMR/K013041/1 / / Medical Research Council / United Kingdom
R01 AG044546 / AG / NIA NIH HHS / United States
U24 AG021886 / AG / NIA NIH HHS / United States
U01 AG032984 / AG / NIA NIH HHS / United States
R01 AG042611 / AG / NIA NIH HHS / United States
RF1 AG053303 / AG / NIA NIH HHS / United States
U01 AG024904 / AG / NIA NIH HHS / United States
G0300429 / / Medical Research Council / United Kingdom
GR082604MA / / Wellcome Trust / United Kingdom
P01 AG003991 / AG / NIA NIH HHS / United States
P50 AG005681 / AG / NIA NIH HHS / United States
P30 AG013846 / AG / NIA NIH HHS / United States
P01 AG026276 / AG / NIA NIH HHS / United States
#U01AG032984 / AG / NIA NIH HHS / United States
P01AG03991 / AG / NIA NIH HHS / United States
G0902227 / / Medical Research Council / United Kingdom
MR/L501517/1 / / Medical Research Council / United Kingdom
NIH P50 AG05681 / AG / NIA NIH HHS / United States
P01-AG003991 / AG / NIA NIH HHS / United States
A2013359S / / PHS HHS / United States
TL1 TR000096 / TR / NCATS NIH HHS / United States
R01-AG044546 / AG / NIA NIH HHS / United States
MR/L010305/1 / / Medical Research Council / United Kingdom